The company manufactures and markets bulk drugs and chemical intermediates, primarily focusing on Triphenyl Phosphine (TPP) and related products for the pharmaceutical industry.
The company operates in a commoditized chemical segment with low margins and returns on capital that barely cover the cost of capital. While they claim a leadership position in TPP, the lack of pricing power is evident in the volatile net margins and the inability to pass on raw material cost fluctuations effectively.
Capital has been deployed into expanding capacity for low-margin intermediates and providing unsecured inter-corporate loans to third parties. The high debt-to-equity ratio and low cash conversion suggest that reinvestment is not yielding high-quality shareholder returns.
The company's collapse was driven by a liquidity trap where interest obligations finally overwhelmed the stagnant cash flows from its commoditized chemical operations. The inability to verify inventory and the lack of balance confirmations, previously flagged by auditors, eventually masked a significant asset impairment that wiped out the remaining equity. As the unsecured loans to third parties proved unrecoverable and the cost of debt rose, the business lacked the pricing power to pass on costs, leading to a terminal squeeze on the already razor-thin margins.
RichFakir rates Roopa Industries Ltd's business quality as poor — 25/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Roopa Industries Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Roopa Industries Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Roopa Industries Ltd's fair value is about ₹21 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →